Leerink Partnrs Upgrades Rhythm Pharmaceuticals (NASDAQ:RYTM) to "Strong-Buy"

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) was upgraded by research analysts at Leerink Partnrs to a "strong-buy" rating in a research report issued on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Rhythm Pharmaceuticals' Q2 2025 earnings at ($0.87) EPS, Q3 2025 earnings at ($0.90) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.49) EPS, FY2026 earnings at ($2.86) EPS, FY2027 earnings at ($2.07) EPS, FY2028 earnings at ($0.42) EPS and FY2029 earnings at $1.28 EPS.

Other research analysts have also recently issued research reports about the company. Stifel Nicolaus boosted their price objective on Rhythm Pharmaceuticals from $78.00 to $94.00 and gave the stock a "buy" rating in a research note on Thursday, May 29th. Wells Fargo & Company boosted their price objective on Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the stock an "overweight" rating in a research note on Monday, April 7th. Needham & Company LLC boosted their price objective on Rhythm Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Wednesday, May 7th. Bank of America upgraded shares of Rhythm Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $63.00 price objective on the stock in a research note on Monday, April 7th. Finally, Leerink Partners assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Monday. They set an "outperform" rating and a $88.00 price objective on the stock. Fourteen equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $91.00.

Rhythm Pharmaceuticals Price Performance

NASDAQ:RYTM traded down $2.34 during trading hours on Monday, reaching $86.70. 1,105,173 shares of the company were exchanged, compared to its average volume of 588,655. The firm has a market cap of $5.52 billion, a price-to-earnings ratio of -30.85 and a beta of 2.26. Rhythm Pharmaceuticals has a 52-week low of $40.61 and a 52-week high of $94.80. The stock has a 50 day simple moving average of $63.88 and a 200 day simple moving average of $59.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.12). The company had revenue of $37.72 million for the quarter, compared to analysts' expectations of $40.43 million. Rhythm Pharmaceuticals had a negative return on equity of 739.62% and a negative net margin of 123.26%. The business's revenue for the quarter was up 25.9% on a year-over-year basis. During the same period in the prior year, the business earned ($2.35) EPS. On average, analysts predict that Rhythm Pharmaceuticals will post -4.32 EPS for the current fiscal year.

Insider Buying and Selling

In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 7,969 shares of the firm's stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $77.78, for a total value of $619,828.82. Following the sale, the insider directly owned 8,509 shares in the company, valued at approximately $661,830.02. This trade represents a 48.36% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Pamela J. Cramer sold 15,572 shares of the business's stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $77.13, for a total transaction of $1,201,068.36. Following the transaction, the insider directly owned 19,209 shares of the company's stock, valued at approximately $1,481,590.17. This trade represents a 44.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 93,673 shares of company stock valued at $7,118,510 over the last 90 days. 6.10% of the stock is owned by corporate insiders.

Institutional Trading of Rhythm Pharmaceuticals

Several hedge funds have recently bought and sold shares of RYTM. First Trust Advisors LP raised its holdings in shares of Rhythm Pharmaceuticals by 67.2% during the fourth quarter. First Trust Advisors LP now owns 118,337 shares of the company's stock valued at $6,625,000 after buying an additional 47,575 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Rhythm Pharmaceuticals in the 4th quarter worth approximately $521,000. SBI Securities Co. Ltd. bought a new position in Rhythm Pharmaceuticals in the 4th quarter worth approximately $37,000. BNP Paribas Financial Markets grew its holdings in Rhythm Pharmaceuticals by 491.0% in the 4th quarter. BNP Paribas Financial Markets now owns 85,249 shares of the company's stock worth $4,772,000 after buying an additional 70,824 shares in the last quarter. Finally, SG Americas Securities LLC bought a new position in Rhythm Pharmaceuticals in the 1st quarter worth approximately $1,042,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.